Stockreport

Better Therapeutics Completes Enrollment of Pivotal Trial for BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes

Better Therapeutics, Inc.  (BTTX) 
PDF Primary endpoint data expected in Q1 2022 SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital ther [Read more]